It's been a topsy-turvy year for the original biotech blue-chip stock, Amgen (NASDAQ:AMGN), which currently finds its shares up just over 1% year to date through Dec. 27.
You may not realize it based on Amgen's vacillating share price, but it's been a transformative year for the company, with six new drug approvals or label expansions since December 2014. Still, many questions await Amgen in 2016. Will the drug approvals keep coming?
You may not realize it based on Amgen's vacillating share price, but it's been a transformative year for the company, with six new drug approvals or label expansions since December 2014. Still, many questions await Amgen in 2016. Will the drug approvals keep coming?
